Core Viewpoint - The company has adjusted its 2024 annual profit distribution cash dividend total from CNY 222,585,426.80 to CNY 222,468,028.71 due to changes in total share capital resulting from the repurchase and cancellation of restricted stock options [1][2] Summary by Sections Adjustment of Profit Distribution - The cash dividend per share remains unchanged at CNY 0.17 (including tax) despite the total amount being adjusted [1] - The adjustment was necessary because the company repurchased and canceled 409,626 shares of restricted stock, affecting the total share capital [2] Pre-Adjustment Profit Distribution Plan - The initial profit distribution plan was based on a total share capital of 1,309,326,040 shares, with a proposed cash dividend of CNY 1.70 per 10 shares [1] - The total profit allocated for distribution was CNY 222,585,426.80, which exceeded 10% of the distributable profit and 30% of the net profit attributable to shareholders [1] Post-Adjustment Profit Distribution Plan - After the cancellation of shares, the total share capital decreased to 1,308,916,414 shares, leading to a new distribution base of 1,308,635,463 shares [4] - The adjusted total profit for distribution is now CNY 222,468,028.71, maintaining the cash dividend of CNY 1.70 per 10 shares [4] - The remaining distributable profit will be carried over to the next fiscal year [4]

证券代码：600713 证券简称：南京医药 公告编号：ls2025-088 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.17元 ? 相关日期 | | | | | 现金红利发放 | | --- | --- | --- | --- | --- | | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | | | | | | 日 | | Ａ股 | 2025/6/27 | － | 2025/6/30 | 2025/6/30 | ? 差异化分红送转： 是 （2）本次差异化分红除权（息）参考价格 根据上海证券交易所的相关规定，公司按照以下公式计算除权（息）开盘参 考价： 除权（息）参考价格=（前收盘价格-现金红利）÷（1+流通股份变动比例） 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 5 日召开的2024年年度股东大会审议通 过。 二、分配方案 截至股权登记日下午 ...

Core Viewpoint - The China General Technology (Group) Holding Co., Ltd. has implemented a warning education campaign to address issues identified in cases of misconduct, aiming to enhance accountability and rectify shortcomings within the organization [1][2][4] Group 1: Warning Education Implementation - The campaign involved over 11,000 party members receiving warning education through the analysis of typical cases [1] - Five typical cases of misconduct were selected for in-depth analysis, accompanied by the production of five educational videos featuring confessions from violators and insights from investigators [1][2] - The goal is to create a closed-loop warning education system that emphasizes self-examination and rectification based on identified issues [2] Group 2: Case Analysis and Recommendations - The China Medical Health Industry Co., Ltd. held a seminar focusing on identifying integrity risks across various business sectors, resulting in a list of issues and corrective measures [3] - The company proposed 16 corrective suggestions in response to a serious misconduct case, aiming to establish comprehensive supervision mechanisms for financial operations [3] Group 3: Future Directions - The organization plans to consolidate and deepen the results of the warning education, ensuring thorough investigation and rectification of issues to drive high-quality development [4]

Core Viewpoint - The legal opinion letter confirms the legality and validity of the procedures, qualifications, proposals, and voting results of the 2024 annual general meeting of Shanghai First Pharmaceutical Co., Ltd. [1][5] Group 1: Meeting Organization - The 2024 annual general meeting is scheduled for June 20, 2025, at the third meeting room on the 20th floor of 681 Xiaomuqiao Road, Xuhui District, Shanghai [1][2] - The meeting was announced on May 31, 2025, on the Shanghai Stock Exchange website, detailing the time, location, agenda, attendees, registration methods, and voting procedures [2][3] Group 2: Meeting Attendance - A total of 2 shareholders and their representatives attended the meeting, holding 100,278,034 shares with voting rights, which represents a significant portion of the total voting shares [3][4] - Additionally, 116 shareholders participated through the online voting system during the designated trading hours on June 20, 2025 [4] Group 3: Meeting Proposals - The meeting included several key proposals such as the 2024 Board of Directors' work report, 2024 Supervisory Board's work report, financial reports, profit distribution plan, and various resolutions regarding board member elections and compensation [4][5] - Proposals related to the financial service agreement with Bailian Group and the cancellation of the Supervisory Board were also discussed [4] Group 4: Voting Procedures and Results - The voting results indicated that proposals requiring a two-thirds majority were approved, while others needed a simple majority, with specific votes counted separately for minority investors [5] - The legal opinion confirms that all voting procedures and results comply with relevant laws and regulations, ensuring the legitimacy of the meeting outcomes [5]

Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 7 at 9:30 AM in Beijing [1][3] - The voting will be conducted through a combination of on-site and online voting systems provided by the Shanghai Stock Exchange [3][4] - The registration for attending the meeting will be open from June 30 to July 2, 2025, and shareholders must present identification and relevant documents [6][5] Group 2 - The meeting will review proposals that have already been approved by the company's board of directors [2][3] - Shareholders can vote through the Shanghai Stock Exchange's online voting system, with specific time slots for voting on the day of the meeting [1][4] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts for the same category of shares [5][4]

Core Viewpoint - The company plans to sign a lease agreement with Tianjin Tai Ping Pharmaceutical Co., Ltd. to rent out a warehouse for three years, aiming to improve asset utilization and generate stable rental income [1][10]. Summary by Sections 1. Overview of the Related Transaction - The company intends to lease a property located at No. 5 Tengda Road, Beichen District, Tianjin, with a usage area of 24,112.59 square meters to Tianjin Tai Ping Pharmaceutical Co., Ltd. for a total contract amount of 14.7858 million RMB, which accounts for 0.19% of the company's latest audited net assets [1][2]. 2. Basic Information of the Related Party - Tianjin Tai Ping Pharmaceutical Co., Ltd. is a subsidiary of the company's controlling shareholder, Tianjin Pharmaceutical Group Co., Ltd., which holds 56.65% of its shares, while the company holds 43.35% [4][11]. 3. Financial Impact and Transaction Details - The lease agreement is based on fair market pricing and is expected to positively impact the company's financial status and operational results, aligning with the interests of the company and all shareholders [10][11]. 4. Approval Process - The board of directors approved the lease agreement, with related directors abstaining from voting. The remaining five non-related directors and all independent directors consented to the proposal [10][11]. 5. Historical Related Transactions - In the past 12 months, the company has engaged in related transactions with the same related party, totaling 17.3275 million RMB, which is 0.22% of the latest audited net assets [2][11].

Group 1 - The core index of the China Securities Index for Food and Major Consumer Goods Retail has shown a decline of 2.40% over the past month, 6.58% over the past three months, and 6.48% year-to-date [1] - The index is composed of listed companies in the food and drug retail sector, reflecting the overall performance of these companies, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the index include Yonghui Supermarket (6.61%), Digital China (6.21%), Wancheng Group (4.68%), Shanghai Pharmaceuticals (4.41%), Yifeng Pharmacy (4.32%), Jiuzhoutong (3.86%), Kidswant (3.41%), Sinopharm (3.25%), Wangfujing (3.17%), and TianKang (3.09%) [1] Group 2 - The market segments represented in the index include 43.94% in pharmaceutical commerce, 21.32% in supermarkets and convenience stores, 20.29% in specialty retail, and 14.46% in department stores [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

每经记者｜王琳 每经编辑｜董兴生 6月18日晚间，重药控股（000950.SZ，股价4.94元，市值85.37亿元）发布公告披露，其于6月18日收到公司控股股东重庆医药健康产业有限公司（以下简称 重庆医健）的告知函，获悉其股权结构拟发生变更。 具体来说，重庆医健的股东重庆渝富控股集团有限公司（以下简称重庆渝富）于6月18日在重庆联合产权交易所集团股份有限公司（以下简称重庆联交所） 公开挂牌转让重庆医健24%股权。 2024年全年，重庆医健实现营业收入和净利润分别为811.75亿元和4.14亿元；2025年第一季度，重庆医健的营业收入和净利润分别为207.57亿元和1.87亿元。 截至2025年一季度末，重庆医健的所有者权益为188.07亿元。 | | 以下数据出自年度审计报告 | | | | --- | --- | --- | --- | | 2024 (年度) | 营业收入 | 营业利润 | 浄利润 | | | 8117500. 21万元 | 57886. 30万元 | 41361. 24万元 | | | 资产总计 | 负债总计 | 所有者权益 | | | 6900556. 26万元 | 5042140.1 ...

Core Viewpoint - The article outlines the management measures for the employee stock ownership plan (ESOP) of Jiuzhoutong Pharmaceutical Group Co., Ltd. for the period 2023-2026, emphasizing compliance, voluntary participation, and risk-bearing principles. Group 1: General Principles - The ESOP will be implemented in strict accordance with relevant laws and regulations, ensuring accurate and timely information disclosure [1][2] - Participation in the ESOP is voluntary, with no forced allocation or distribution to employees [2] Group 2: Plan Implementation Procedures - The company will solicit employee opinions through representative meetings before implementing the ESOP [3] - The board of directors must approve the ESOP draft and ensure that related directors abstain from voting [3][4] - A legal opinion will be obtained before the shareholders' meeting to review the ESOP [4] - The shareholders' meeting will vote on the ESOP using a combination of on-site and online voting methods [4] Group 3: Funding and Stock Sources - The total amount of funds to be raised for the ESOP is approximately 461.69 million yuan, with each share priced at 1 yuan [5] - The ESOP will acquire stocks from the company's repurchase account and through market purchases [5] - The total scale of the ESOP is planned to be around 48.60 million shares, accounting for approximately 2.59% of the company's total share capital [5] Group 4: Lock-up Period and Performance Assessment - The lock-up period for the ESOP shares is set at 12 months from the distribution date of each batch [6][7] - Performance assessments will determine the returns for participants based on individual performance ratings [7] Group 5: Management Structure - The ESOP will be managed by a management committee elected by the participants, which will oversee daily operations and asset management [8][9] - The management committee is responsible for making decisions regarding the sale and distribution of the ESOP's assets [9] Group 6: Rights and Obligations of Participants - Participants have the right to request cash distributions or stock transfers after the lock-up period [14] - Participants are obligated to comply with the management committee's decisions regarding the ESOP [14][15]

第二条 九州通医药集团股份有限公司（以下简称"公司"）系依照《公司 法》和其他有关规定成立的股份有限公司。 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）和其他有关规定，制定本章程。 公司经湖北省商务厅（鄂商资【2008】133 号文）批准，在九州通集团有限 责任公司的基础上以整体变更方式发起设立。公司在湖北省市场监督管理局注册 登记，取得营业执照，统一社会信用代码为 9142000071451795XA。 第三条 公司于【2010 年 10 月 14 日】经中国证券监督管理委员会（以下简 称"中国证监会"）核准，首次向社会公众发行人民币普通股【150,000,000】股， 于【2010 年 11 月 2 日】在【上海证券交易所】上市。 公司于【2024 年 7 月 5 日】经中国证监会核准，公司向特定对象发行优先 九州通医药集团股份有限公司 章程 （2025 年 6 月修订） 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三 ...